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Since 1967, Rifamaycin (RIF) has been used as a first line antibiotic treatment for 
tuberculosis (TB), and it remains the cornerstone of current short-term TB treatment. Increased 
occurrence of RIF-resistant (RIFR) TB, ~41% of which results from the RpoB S531L mutation in 
RNA polymerase (RNAP), has become a growing problem worldwide. In this study, we 
determined the X-ray crystal structures of the Escherichia coli RNAPs containing the most 
clinically important S531L mutation and two other frequently observed RIFR mutants, RpoB 
D516V and RpoB H526Y. The structures reveal that the S531L mutation imparts subtle if any 
structural or functional impact on RNAP in the absence of RIF. However, upon Rifampin (RMP) 
binding, the S531L mutant exhibits a disordering of the RIF binding interface, which effectively 
reduces the RIF affinity. In contrast, the H526Y mutation reshapes the RIF binding pocket, 
generating significant steric conflicts that essentially prevent RIF binding. While the D516V 
mutant does not exhibit any such gross structural changes, certainly the electrostatic surface of 
the RIF binding pocket is dramatically changed, likely resulting in the decreased affinity for RIF. 
Analysis of interactions of RMP with three common RIFR mutant RNAPs suggests that 
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Tuberculosis (TB) is one of the world’s most common and deadliest infectious diseases 
and ranks along with HIV as a leading cause of death worldwide (World-Health-Organization, 
2016). In 2015, there were an estimated 10.4 million new TB cases and 1.8 million TB-
associated deaths (including 0.4 million TB deaths among HIV-positive people) worldwide 
(ibid). TB, which is caused by infection with Mycobacterium tuberculosis (MTB), is also one of 
the most contagious pathogens; it is estimated that nearly one-third of the global population is 
infected by MTB, primarily in Asia and Africa. Up to 5-10% of the residents in the United States 
also carry MTB, which leads to thousands of TB-associated deaths annually including patients 
coinfected with HIV. Treatment of TB has remained essentially unchanged for the last 40 years, 
and it represents a multi-drug regimen administered for a 6- to 9- month period. Currently, TB 
treatment practices raise growing concerns due to increasing frequency of outbreaks of multi-
drug resistant TB (MDR-TB) (Lienhardt et al., 2010, Siddiqi & Kumar, 2009). 
A natural antibiotic Rifamycin (RIF) and its semisynthetic derivatives including 
Rifampin (or Rifampicin, RMP) (Fig. 1A) have been widely used to treat mycobacterial 
infections and remains the cornerstone of TB treatment (Sensi, 1983, Aristoff et al., 2010). RIF 
targets bacterial RNA polymerase (RNAP) and its binding site is located on the RpoB (or β 
subunit) at the DNA:RNA binding cleft (Fig. 1B) blocking RNA extension beyond the length of 
2-3 nt (Campbell et al., 2001). Owing to their high efficacy even against latent forms of MTB 
(e.g., “sterilizing activity”), RIF derivatives have been the first line drug for TB treatment since 
their introduction into clinical practice in the 1960s. However, a substantial number of patients, 
estimated to have been 480,000 in 2015 (World-Health-Organization, 2011), become infected 
with RIF-resistant (RIFR) strains or develop resistance during the course of antibiotic treatment. 
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RIFR strains have spontaneous mutations (frequency of 10-8) within 4 regions of RpoB (also 
known as the RIF resistance-determining region, RRDR) including the N-terminal cluster 
(residue 146, E. coli RNAP numbering) and clusters I (residues 507-533), II (residues 563-572) 
and III (residue 687) (Fig. 2) (Goldstein, 2014, Sandgren et al., 2009). The vast majority of the 
mutations are single amino acid substitutions (resulting from single nucleotide mutations) 
concentrated in cluster I, which is highly conserved among bacterial RNAPs, but not archaeal or 
eukaryotic RNAPs. A crystal structure of the Thermus aquaticus RNAP core enzyme in complex 
with RMP revealed that the lateral side of the RMP napthalene ring/ansa bridge binds to the β 
subunit surface comprising RRDR cluster I and the top of the napthalene ring is covered by the β 
subunit loops including RRDR cluster II and fork loop 2 (residues 534-541) (Campbell et al., 
2001) (Fig. 2B). The structure also revealed a number of amino acid residues that directly 
interact with RMP via hydrogen bonding or van der Waals interactions (Fig. 1B). Although 90 
non-synonymous rpoB mutations at 33 codons in the RRDRs were found in clinical RIFR MTB 
isolates, around 85% of isolates involve the amino acid substitutions at Ser 531 to Leu (S531L, 
~41%), His 526 to Tyr (H526Y, ~36%) and Asp 516 to Val (D516V, ~9%) (Fig. 2A) (Campbell 
et al., 2001, Artsimovitch et al., 2005, Gill & Garcia, 2011) (according to convention, we will 
use the numbering of the E. coli RNAP when referring to mutations within the RRDR throughout 
the manuscript). 
RIFR MTB strains have been studied for a long time, however, the majority of the 
biochemical studies reported to date have been conducted using wild-type (WT) and RIFR E. coli 
RNAPs. Selection for RIFR mutants of the E. coli versus MTB RNAPs produce similar, but 
significantly distinct pools of mutations (Fig. 2A). In E. coli, the Ser to Leu substitution at 
residue 531 has not yet been observed, while the Ser to Phe substitution is most frequently 
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observed at this position. This observation can be explained, at least in part, by the different 
codon usages for serine in E. coli (TCT) versus MTB (TCG). For the Ser to Leu substitution at 
position 531, E. coli rpoB would require two nucleotide changes (TCT to TTG/TTA) in contrast 
to the single nucleotide change (TCG to TTG) for MTB rpoB (Goldstein, 2014), while the Ser to 
Phe mutation in the E. coli rpoB would require a single nucleotide change (TCT to TTT). 
The RNAP and RIF interaction has been well characterized by analyses of the crystal 
structures of the RNAPs from Thermus aquaticus, Thermus thermophilus and E. coli in complex 
with RIF derivatives (Campbell et al., 2001, Molodtsov et al., 2013, Artsimovitch et al., 2005); 
however, the molecular interactions responsible for resistance by the RNAP mutations remain 
unclear. The nature of the interaction of each amino acid residue with RIF is different (Fig. 1B) 
and some RIFR mutations not only disrupt the interaction (e.g., hydrogen bond, salt bridge or van 
der Waals interactions) with RIF but may also perturb the shape of the RIF binding pocket, 
making it difficult to confidently attribute the resistance to a specific change in molecular 
interaction using the structure of WT RNAP•RIF complex as a reference. 
WT and RIFR mutants of the MTB RNAPs can be prepared from co-overexpression 
systems in E. coli cells (Gill & Garcia, 2011, Banerjee et al., 2014), however, the crystallization 
and structure determination of the MTB RNAP remain to be established. Previously, we and 
other groups reported that E. coli RNAP prepared from a co-overexpression system can be used 
for crystallization and structure determination (Murakami, 2013, Zuo et al., 2013, Bae et al., 
2013, Degen et al., 2014), which opens new avenues for structural studies of bacterial RNAP, 
including structure determination of RNAP mutants. To reveal the structural basis of RIF 
resistance, we crystallized E. coli RNAP containing clinically important RIFR mutations in apo-
form and also in complex with RMP and solved their structures. These structures reveal that the 
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molecular interactions responsible for RIF resistance by each mutant are diverse and 
significantly more complex than previously predicted based on the co-crystal structures of the 
WT RNAP in complex with RIF derivatives (Campbell et al., 2001, Artsimovitch et al., 2005, 
Campbell et al., 2005, Nigam et al., 2014, Gill & Garcia, 2011). Our study also provides a basis 
for structure-guided development of improved RIFs that should regain the ability to inhibit 
bacterial transcription in the context of these current antibiotic resistant mutations. 
 
RESULTS 
Preparation and characterizations of the RIF
R
 RNAPs 
Amino acid sequences of the RRDR cluster I are highly conserved in bacteria (Fig. 2A), 
however, some bacterial RNAPs are less sensitive (e.g., Thermus aquaticus) or naturally 
resistance (e.g., Borrelia burgdorferi) to RIF (Campbell et al., 2001, Alekshun et al., 1997). 
Therefore, the effect of amino acid substitution in the RRDR cluster I (D516V/D435V, 
H526Y/H445Y and S531L/S450L in E. coli/MTB RNAPs) on the RMP sensitivity should be 
compared between these enzymes to validate E. coli RNAP as a convenient model system for 
investigating the molecular mechanism of RIF resistance of the MTB RNAP mutants. 
For preparing RIFR mutant E. coli and MTB RNAPs (Fig. 3A), we used overexpression 
systems in an E. coli host strain for the RNAP core and/or holo enzymes (Gill & Garcia, 2011, 
Banerjee et al., 2014), which utilize vectors carrying the genes of the RNAP subunits, from 
either E. coli or MTB, under control of a strong T7 promoter.  The transcriptional activities of 
the WT RNAPs from E. coli and MTB are completely inhibited with 200 nM RMP, whereas the 
activities of RIFR RNAPs are not influenced by RMP at this concentration (Table 1). 
Transcription assays of the RIFR RNAP mutants in the presence and the absence of 200 nM RMP 
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indicated that contamination by chromosomally-encoded E. coli RNAP in the purified MTB 
RIFR RNAPs is negligible, while the E. coli RIFR RNAPs had ~25% contamination (Fig. 3B). 
The effect of RNAP mutation on the RMP sensitivity was evaluated by determining the 
IC50 values for RMP using a promoter-dependent transcription assay (see MATERIALS AND 
METHODS) with RNAP holoenzymes (E. coli σ70 holoenzyme nd MTB σA holoenzyme) (Table 
1, Fig. S1). Three RIFR mutants tested in this study are classified into two groups according to 
their RMP sensitivities; the D516V and S531L mutants of E. coli RNAP are less sensitive to 
RMP (IC50 398 and 263 µM, respectively), whereas the H526Y mutation makes this enzyme 
essentially insensitive to RMP (IC50 ≥ 2 mM). Corresponding RIF
R mutations in MTB RNAP 
were also classified into the same groups; the D435V and S450L mutants are less sensitive to 
RMP (IC50 880 and 789 µM, respectively), whereas the H445Y mutant is essentially insensitive 
to RMP (IC50 > 2 mM). These results support the use of the E. coli RNAP as a model of the 
MTB RNAP in probing molecular mechanisms of RIF resistance. 
 
Structure determination of the RIF
R RNAP holoenzyme in complex with RMP 
To minimize the amont of WT RNAP in the RIFR RNAP crystals, we modified the 
RNAP purification procedure including extensive washing of the RIFR RNAP bound Ni-column 
before eluting proteins by imidazole. Transcription assay of the RIFR RNAPs in the presence and 
the absence of RMP indicates that contaminations by chromosomally-encoded WT RNAP in the 
purified RIFR RNAPs are negligible (Fig. S3). 
The asymmetric unit of the E. coli RNAP crystals contains two 440 kDa RNAPs with 
almost identical structures, designated RNAPA and RNAPB. Since for both complexes, the 
electron density maps of RMP located in its binding site on RNAPA were better than those for 
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RNAPB, the structural analysis presented in this study is based only on RNAPA. Although RMP 
binds poorly to RIFR RNAPs at a therapeutic concentration (~10 µM) (Aristoff et al., 2010), we 
took advantage of soaking a high concentration (1-2 mM) of RMP into the pre-existing RNAP 
crystal to obtain RNAP•RMP complexes. This allowed detailed analyses of the molecular 
interfaces between the RRDR and RMP in the RIFR RNAPs. The electron density maps of the 
WT RNAP•RMP, S531L RNAP•RMP and D516V RNAP•RMP complexes show unambiguous 
densities in the RIF binding pocket that match well with the ansa-naphthalene core of RMP (Fig. 
S2). In contrast, the H526Y mutant did not show any electron density corresponding to RMP, 
consistent with its extreme resistance to RMP (Table 1). We conclude that at this high 
concentration RMP inhibits the H526Y RNAP non-specifically. 
 
Structural basis of the RIF resistance by the S531L mutation 
In the WT RNAP•RMP complex, the S531 residue is located in the deep cleft of the RIF 
binding pocket and forms a hydrogen bond with the phenol on C8 (O2 atom) of the RMP 
napthalene ring (Fig. 1B) and the top of the napthalene ring is covered by β subunit loops, 
including fork loop 2 (residues 534-541, Fig. 4A) (Molodtsov et al., 2013, Campbell et al., 2001, 
Artsimovitch et al., 2005). 
In the crystal structure of S531L RNAP•RMP complex, however, a major difference is 
observed around the β subunit fork loop 2 of which the electron density is weak and scattered 
compared to its counterpart in the WT RNAP•RMP complex (Figs. S2A and C). Consequently, 
about half of the RMP naphthalene ring is exposed to solvent (Fig. 4A, right), reducing ~40% of 
the contact area between RNAP and RMP (386 Å2 and 244 Å2 in the WT and S531L mutant, 
respectively). This alteration dramatically reduces the van der Waals interactions resulting in a 
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large loss of binding free energy, and is consistent with drastic increase in IC50 of RMP for the 
S531L mutant compared to WT RNAP (Table 1). Interestingly, fork loop 2 is ordered in the 
S531L mutant without RMP bound (Fig. S2B), suggesting that the collision between RMP and 
the Leu side chain of the S531L mutant pushes fork loop 2 away, causing the observed disorder 
(Fig. 4B). 
 
Structural basis of the RIF resistance by the H526Y mutation 
In the WT RNAP•RMP complex, the H526 residue is involved in forming the back wall 
of the RIF binding cavity and may form a hydrogen bond with oxygen atoms of the ansa bridge 
and/or the Q513 side chain (Fig. 1B), the latter of which defines the RIF binding wall within 
RRDR cluster I. 
We etermined the crystal structure of the H526Y RNAP mutant at 3.6 Å resolution 
(Table 2). The structure showed large rearrangements of main chain around the RRDR (residues 
512-520 and 756-766) due to the H526Y substitution, which alters the shape of RIF binding 
pocket (Fig. 5A). Due to its very poor affinity for RMP, we could not obtain a crystal structure 
of the H526Y RNAP•RMP complex. Modeling RMP from the WT RNAP•RMP complex into 
the RIF-binding pocket of H526Y RNAP shows that the rearranged RIF binding pocket would 
sterically clash with the rigid plane of the hydrophobic ansa-bridge (from C16 to C23 positions), 
particularly at C19 position (Fig. 5B), therefore effectively preventing RIF binding and making 
the mutant virtually insensitive to RIF (Table 1). 
 
Structural basis of the RIF resistance by the D516V mutation 
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In WT RNAP and the RNAP•RMP complex, the D516 residue forms part of the sidewall 
of the RIF binding pocket and assists in positioning RMP to form two hydrogen bonds between 
the F514 main chain (both amino and carboxyl groups) and the RMP ansa bridge (OH at C23, 
O9 atom and keto oxygen at C35, O8 atom) (Fig. 1B). The D516 side chain also contributes to 
RMP binding by van der Waals interactions with the RMP ansa bridge around position C20 
and/or by charge neutralization of basic residues (R529 and R687) in the RIF binding site to 
facilitate binding the relatively apolar RMP (Fig. 6A). 
There is no major structural change in RRDR cluster I in the D516V mutant. The 
structure of the D516V RNAP•RMP complex is also similar to the WT RNAP•RMP complex 
(Fig. S2D). A significant difference between the WT and D516V RNAPs is the electrostatic 
distribution of the RIF binding pocket around C17 to C20 of the RMP ansa bridge, which 
becomes more basic due to losing the Asp side chain (Fig. 6B). The altered electrostatic 
distribution of the RIF binding pocket may make it less favorable for binding the relatively 
apolar RMP (Table 2). 
 
DISCUSSION  
This study provides the first direct structural investigation of the molecular details 
responsible for RIF resistance in the clinically important RpoB mutants isolated in MTB. We 
determined the crystal structures of the E. coli RNAP including the RIFR mutants D516V, 
H526Y and S531L and showed that each mutation elicits different structural and/or surface 
electrostatic potential changes which make the RIF binding interface less favorable for binding 
RMP (Figs. 4, 5 and 6). The conformational changes around the RRDR associated with the 
H526Y and S531L RNAP mutations are evident at the resolution of these structures (3.6-3.8 Å) 
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(Table 2). These changes alter the shape of RIF binding pocket (H526Y mutation) and disorder 
the β subunit fork loop 2 upon RMP binding (S531L mutant) and allow us to deduce the 
structural basis for RIF resistance. 
Using the WT RNAP•RMP complex structure as a template, several studies have 
previously modeled the RNAP structures containing RIFR mutations using molecular dynamics 
simulations or simple amino acid substitutions to postulate the molecular mechanisms of RIF 
resistance (Campbell et al., 2001, Artsimovitch et al., 2005, Campbell et al., 2005, Nigam et al., 
2014, Gill & Garcia, 2011). The predictions about the D516V RNAP made by Campbell et al. 
(Campbell et al., 2001) based on the T. aquaticus RNAP•RMP complex structure are consistent 
with the effects observed in the D516V RNAP•RMP complex in this work (Fig. 6). However, 
none of the previous work identified the RIFR mechanisms of the S531L and H526Y mutants 
which were revealed in our study. Analysis of the structures of S531L RNAP with and without 
RMP revealed a bipartite mechanism resulting in the RIFR phenotype. The two aspects of the 
S531L RMP resistance are: 1) elimination of a key hydrogen bond between the Ser531 side 
chain and the phenol on C8 of the naphthalene ring; and 2) disordering of fork loop 2 that may 
result from a steric clash between RMP and the Leu side chain at position 531 (Fig. 4D). The 
disorder of fork loop 2 disrupts RNAP•RMP contacts and also exposes hydrophobic segments of 
RMP to solvent, which is unfavorable for stable RNAP•RMP complex formation. In the absence 
of bound RMP, the S531L mutation did not exhibit any gross structural change in the RIF 
binding site. In contrast, the H526Y mutation reshapes the RIF binding site and sterically blocks 
RMP binding to RNAP (Fig. 5), resulting in insensitivity to RMP. These differences between 
mutation-specific RIF pocket architectures underscore the need to experimentally determine the 
structures of RIFR RNAPs to elucidate the precise resistance mechanisms. 
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Crystal structures of the mutant RNAPs reported here provide a structural foundation for 
designing RIF derivatives that may regain potency against the RIFR mutants and MDR-TB. 
Development of resistance to any new RIF derivative is possible via new mutations in the 
RRDR, however, such additional mutations may compromise the transcriptional integrity and 
further diminish the fitness (Song et al., 2014, Comas et al., 2012, Gagneux et al., 2006) of the 
RNAP rendering the resulting MTB strain nonviable. Another important advantage of 
developing new RIF derivatives is that this approach exploits the widely used and well-studied 
rifamycin scaffold and may likely avoid many obstacles common for development of new 
antibiotics such as the problems of drug permeability through bacterial membranes, human 
toxicity and specificity. 
Based on our analysis of the structure of the S531L RNAP•RMP complex, we postulate 
that reducing the steric constraints around the methyl on C7 of the naphthalene ring imposed by 
the S531L substitution may improve the affinity of RMP. The largely intact RIF binding pocket 
except the fork loop 2 observed in the S531L RNAP and the S531L RNAP•RMP complex 
suggests that the reduced affinity of the S531L RNAP for RIF could be compensated for by the 
introduction of additional contact groups to the C3/C4 tail of RIF, such as in some 
benzoxazinorifamycins, which we previously designed to interact with the σ finger (Molodtsov 
et al., 2013) and a bipartite inhibitor connecting rifamycin and GE23077 reported by Ebright and 
colleagues (Zhang et al., 2014). In contrast, the significant structural changes of RRDR cluster I 
found in the H526Y mutant suggest that major modifications of the RIF ansa bridge backbone 
would be required for binding in the significantly altered RIF binding site of the H526Y mutant. 
The semi-synthetic nature of RMP precludes chemical manipulations to the RIF backbone by 
traditional chemical approaches; however, recent advances in the bioorganic synthesis of RIF 
Page 12 of 33Molecular Microbiology










derivatives with altered core backbone by means of genetic engineering may provide an 
alternative approach to solve this problem (Nigam et al., 2014). 
The work reported here has even broader potential application for interpreting new 
instances of resistance that are bound to arise as the clinical use of RIF derivatives expands 
beyond treatment of TB. For example, several other RIF derivatives (e.g., Rifabutin and 
Rifapentine) have been approved for clinical use in the US and other countries to treat infections 
caused by Mycobacterium leprae, Mycobacterium avium-intracellulare and Chlamydophila 
pneumoniae. Most recently, another RIF derivative, Rifaximin (Xifaxan), gained FDA approval 
to treat E. coli-born irritable bowel syndrome with diarrhea (also known as "travelers' diarrhea"). 
 
MATERIALS AND METHODS 
Protein expression and purification 
For crystallization of RNAPs, the RIFR RNAP core enzymes were overexpressed in 
BL21(DE3) cells transformed with pVS10-based vectors (encoding rpoA, rpoB, rpoC plus C-
terminal His6-tag and rpoZ) (Belogurov et al., 2007) carrying the corresponding mutations in 
rpoB. The σ70 RNAP holoenzymes were prepared as described previously (Murakami, 2013) 
with modifications. To minimize amount of WT RNAP in the RIFR RNAPs, we purified RIFR 
RNAP core enzymes by a 15 mL Ni-Separose HP column chromatography (GE Healthcare) 
including extensive washing of RIFR RNAP bound resin with buffers containing 1 M NaCl (15 
column volumes) and 20 mM imidazole (10 column volumes) before eluting proteins by 200 
mM imidazole. The RNAP core enzyme was additionally purified by heparin column 
chromatography followed by mixing σ70 factor to reconstitute holoenzyme and by removing 
excess σ70 by size-exclusion Superdex 200 column chromatography (GE Healthcare). In vitro 
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promoter-dependent transcription assay of the RIFR RNAP mutants in the presence and the 
absence of RMP indicate that contaminations by chromosomally-encoded WT RNAP in the 
purified RIFR RNAPs are negligible (Fig. S3). 
E. coli and MTB RNAP holoenzmes used for in vitro transcription assays were prepared 
as follows. WT and RIFR MTB RNAP holoenzymes were overexpressed in BL21(DE3) cells 
transformed with three of the Duet expression system vectors as described in (Banerjee et al., 
2014) with some modifications. The genes encoding rpoB and rpoC were subcloned into pET 
Duet and rpoA and sigA in the pACYC_Duet vector; a 10xHis tag was placed on the N-terminus 
of the rpoA. The third expression vector used, carrying the rpoZ gene, was pRSF instead of 
pCDF. 
E. coli RNAP holoenzymes were overexpressed in terrific broth supplemented with 1 
mM ZnSO4 and induced as described in (Banerjee et al., 2014), with the addition of a second 
expression vector, pRFS-Sig70 encoding rpoD. BL21(DE3) cells transformed with the WT or 
RIFR MTB RNAP holoenzyme expression vectors were grown to an OD600 of 0.4 in terrific broth 
supplemented with 1 mM ZnSO4 and induced with 0.5 mM IPTG for 16 hrs at 16 °C as 
described in (Banerjee et al., 2014).  Cells were resuspended in 20 mL lysis buffer (20 mM Tris-
HCl (pH 8.0), 200 mM NaCl, 20 µM ZnCl2, 5% glycerol, 2 mM β-mercaptoethanol, 1 mM 
PMSF and 1X Roche cOmplete ULTRA protease cocktail). Cells were lysed by sonication and 
clarified by centrifugation at 25,000xg for 45 min. The RNAP was precipitated by addition of 
polyethyleneimine (pH 7.9) to 0.6% followed by centrifugation at 6,000xg for 10 min. The pellet 
was resuspended in 12 mL lysis buffer containing 500 mM NaCl, followed by centrifugation at 
6,000xg for 10 min. After centrifugation again and discard of the supernatant, the RNAP was 
solubilized in 20 mL lysis buffer containing 1 M NaCl. The RNAP was precipitated by adding 
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ammonium sulfate to 60% followed by a 60 min incubation at 4°C. The RNAP precipitate was 
pelleted by centrifugation (6,000xg for 10 min) and the ammonium sulfate pellet was 
resuspended and dialyzed overnight (20 mM Tris-HCl (pH 8.0), 75 mM NaCl, 20 µM ZnCl2,  5% 
glycerol, 2 mM β-mercaptoethanol). The dialyzed RNAP solution was applied to a 5 mL Source 
15S column (GE Healthcare) in TGEB (10 mM Tris-HCl (pH 8.0), 5% glycerol, 0.1 mM EDTA, 
5 mM β-mercaptoethanol) with 50 mM NaCl and eluted over a linear gradient to 1 M NaCl. 
Isolated holoenzyme was then further purified on a 1 mL HisTrap HP column. RNAP was 
applied to the column in 10 mM Tris-HCl (pH8.0), 20 mM NaCl, 5% glycerol, 5 mM β-
mercaptoethanol and eluted over a linear gradient to 500 mM imidazole. The peak containing 
holoenzyme was then applied to a 5 mL Source 15Q columns (GE Healthcare) in TGEB with 50 
mM NaCl and eluted over a linear gradient to 1 M NaCl.  Purified RNAP holoenzyme was 
dialyzed into storage buffer (40 mM Tris-HCl (pH 7.9), 200 mM NaCl, 0.1 mM EDTA, 1 mM 
MgCl2, 20 µM ZnCl2, 50% glycerol, and 5 mM DTT) and stored at -20ºC. 
 
Crystallization and X-ray structure determination of the E. coli RNAP σ
70
 holoenzyme in 
complex with RMP  
Crystals of E. coli RNAP σ70 holoenzymes for the X-ray crystallographic study were 
prepared as described previously (Murakami, 2013). The crystals of the RNAP•RMP complex 
were prepared by soaking RNAP crystals in a solution (0.1 M HEPES-HCl (pH 6.7), 0.2 M Ca 
Acetate, 30% PEG400, 10 mM DTT) containing 1 mM RMP for D516V and S531L RNAPs and 
2 mM RMP for H526Y RNAP overnight at 22 °C followed by a flash freeze in liquid nitrogen. 
The crystallographic datasets were collected at the Macromolecular Diffraction at the 
Cornell High Energy Synchrotron Source (MacCHESS) (Cornell University, Ithaca, NY) and the 
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data were processed by HKL2000 (Otwinowski & Minor, 1997). We determined the resolution 
limit of each crystallographic dataset based on the criteria (CC1/2 > 20 % and completeness > 
80 %) introduced by Karplus and Diederichs (Karplus & Diederichs, 2012), who showed that the 
Rmerge statistic commonly used to evaluate data quality should not be used and the commonly 
used criteria (<I>/σI > 2) for determining the resolution limit results in the loss of useful 
crystallographic data for the structure refinement. 
The structures were solved by molecular replacement using the Phenix suite of programs 
(Afonine et al., 2010) and the E. coli RNAP structure (Murakami, 2013) as an initial model for 
the rigid body and positional refinements with non-crystallographic symmetry and reference 
structure restraints to avoid over-fitting the data (Rfree – Rwork is less than 6%), and to maintain 
the Ramachandran outliers less than ~1%. The resulting maps were used in the Coot program 
(Emsley & Cowtan, 2004) to introduce amino acid replacements of RMPR mutation. Final 
coordinates and structure factors were submitted to the PDB with ID codes listed in Table S2. 
 
In Vitro Transcription Assays 
An in vitro plasmid based transcription assay using a Malachite Green Aptamer (MGA) 
gene (Scharf et al., 2016) that was previously developed for high-throughput screening was 
modified for these studies.  Individual modified pTZ18U vectors containing the E. coli rrnB P1 
(-66 to +5) and MTB rrnA P3 (-55 to +15) ribosomal RNA promoters followed by 4 consecutive 
repeats of DNA encoding the MGA and three consecutive repeats of the synB artificial 
terminator sequence were prepared, pMGA4-Ec-rrnB1-SynBx3 and pMGA4-Mt-rrnA3-SynBx3, 
respectively. The synB terminator was shown to terminate transcription with a 88% and 98% 
termination efficiency for E. coli and M. bovis RNAPs, respectively (Czyz et al., 2014). 
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The buffer for determining the RMP IC50s for the E. coli RNAP holoenzymes was: 20 nM 
pMGA4-Ec-rrnB1-SynBx3, 40 mM Tris-HCl (7.5 at 22 °C), 50 mM KCl, 10 mM MgCl2, 0.01% 
Triton X-100, 1 mM DTT, 500 µM each NTP. For MTB RNAP holoenzymes, 50 nM pMGA4-
Mt-rrnA3-SynBx3, 40 mM Tris-HCl (pH 8.0 at 37°C), 150 mM potassium glutamate, 10 mM 
MgCl2, 0.1 mM EDTA, 25 µg/mL BSA, 1 mM DTT, 500 µM each NTP was used.  For WT E. 
coli and MTB RNAPs, 10 nM of holoenzyme was used, and for RIFR E. coli and MTB RNAPs, 
100 nM enzyme was used.  In all cases 3-fold excess of the corresponding purified σ factor was 
also added.  RMP added to the assays was dissolved in DMSO; therefore DMSO was added to a 
final concentration of 4% (which had a negligible effect on the assay) in all assays.  RMP was 
allowed to incubate with holoenzyme for 30 min prior to the addition of template DNA and 
NTPs. Reactions were incubated at 37°C for 90 min, followed by quenching on ice with addition 
of ice cold malachite green (MG) in water to a final concentration of 75 µM MG. Fluorescence 
was detected at excitation and emission wavelengths of 628 nm and 660 nm, respectively, using 
a BioTek Synergy2 plate reader. The fluorescence readings were normalized to % activity, 
plotted against the log [RMP] and fit by nonlinear regression to Eq. (1) where M0 = log of 
compound concentration, M1 = log of IC50, M2 = hill slope, M3 = lower limit of the curve, and 
M4 = upper limit of the curve.  Three replicate sets of data for each RNAP were individually fit 
and the averages and standard deviations of the three individual IC50s are reported in Table 1.  
(For visualization, the average % activity for each [RMP], with their standard deviations as error 
bars, are plotted in Supplementary Figure 1.)  The final concentrations of the WT RNAPs were 
10 nM, therefore the minimum IC50 which can be determined for both E. coli and MTB WT 
RNAPs was 5 nM. 
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To determine contamination by chromosomally-encoded WT E. coli RNAP, transcription 
assays for the MTB and E. coli RMPR RNAP mutants were conducted in the presence and the 
absence of 200 nM RMP. The results indicate that such contamination in MTB RNAP 
preparations is negligible, while ~25% of E. coli RIFR RNAP preparations were contaminated 
with endogenous WT RpoB (see Fig. 3B). 
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Table 1: RNAP IC50 values for Rifampin (RMP) 
E. coli RNAPs WT D516V H526Y S531L 
RMP IC50 (µM) < 0.005 398 (±118)
1 ≥ 2 mM2 263 (±26)1 
MTB RNAPs WT D435V H445Y S450L 
RMP IC50 (µM) < 0.005 880 (±176)
1 NDI3 789 (±249)1 
 
1 The values are means of three individual determinations and the errors are the standard 
deviations of those means. All experiments were conducted in triplicate. 
2 ~50% inhibition at 2 mM, but an IC50 was not able to be confidently determined. 
3 NDI = no detectable inhibition at 2 mM 
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Table 2: Data collection and refinement statistics 
 
Complex WT•RMP S531L S531L•RMP H526Y D516V D516V•RMP 
PDB code XXXX XXXX XXXX XXXX XXXX XXXX 
Data collection       
Space group P212121 P212121 P212121 P212121 P212121 P212121 
Cell dimensions       
a   (Å) 188.96 187.22 187.37 185.36 184.83 187.81 
b   (Å) 204.43 204.43 205.95 206.28 205.04 206.67 
c(Å) 313.62 310.59 309.69 308.69 307.35 310.29 
       
Resolution (Å)† 30 – 3.8 30 – 3.9 50 – 3.8 30 – 3.6 30 – 3.4 30 – 4.1 
Total reflections 1,016,432 483,112 406,435 825,582 688,252 721,187 
Unique reflections 119,630 86,257 92,344 134,049 144,355 96,868 
Redundancy 8.2 (7.7) 5.6 (5.5) 4.4 (3.8) 6.2 (5.6) 4.8 (3.9) 7.4 (5.9) 
Completeness (%) 100 (100) 81.3 (82.7) 86.9 (80.6) 97.3 (87.2) 90.5 (84.8) 99.8 (98.3) 
I / σ 9.8 (0.6) 11.6 (0.8) 9.1 (0.7) 12.0 (1.2) 9.7 (0.8) 13.9 (0.8) 
Rsym (%) 15.6 (>100) 8.2 (>100) 17.2 (88.1) 11.3 (86.9) 10.8 (>100) 11.2 (>100) 
CC1/2
‡ (0.274) (0.634) (0.604) (0.665) (0.259) (0.537) 
       
Refinement       
Resolution (Å) 30 – 3.8 30 – 3.9 30 – 3.8 30 – 3.6 30 – 3.4 30 – 4.1 
Rwork (%) 24.8 26.0 23.0 24.6 27.7 24.3 
Rfree (%) 29.6 30.7 28.6 30.5 31.1 28.7 
       
B factors (Å2) 188.3 195.3 210.6 157.4 163.0 233.1 
R.m.s deviations       
Bond length (Å) 0.017 0.004 0.0057 0.022 0.011 0.008 
Bond angles (°) 1.56 0.95 1.002 2.15 1.66 1.17 
Ramachandran       
     Favored (%) 91.5 91.3 91.4 91.5 91.1 91.3 
     Outliers (%) 0.8 0.7 0.8 0.8 1.1 0.8 
 
Data sets were collected at MacCHESS, Ithaca, NY 
*Highest resolution shells are shown in parentheses 
†Resolution limits are provided using the CC1/2 > 20 % criterion (Karplus & Diederichs, 2012) 
and completeness higher than 80 %. 
‡CC1/2 = percentage of correlation between intensities from random half-datasets (Karplus & 
Diederichs, 2012). 
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Figure 1. The RIF binding pocket of bacterial RNAP 
(A) Chemical structure of Rifampin (RMP). The five oxygen atoms forming hydrogen bonds 
with the RIF binding pocket of RNAP are shown by red circles and labeled. 
(B) Schematic drawing of RNAP β subunit interactions with RMP (left, side vide of the ansa-
bridge; right, top view of the naphthalene ring). Residues participating in hydrogen bonds are 
shown in stick models, with hydrogen bonds depicted as dashed lines. D516 and H526 are also 
shown as stick models. Three amino acid residues investigated in this study are highlighted by 
red. 
 
Figure 2. Sequence alignment spanning RIF resistance-determining regions (RRDRs) of the 
E. coli, T. thermophilus and MTB RpoB (β subunit) of RNAP 
(A) RRDRs are indicated above the amino acid sequences. Amino acids that are identical among 
the three species are shown as gray background. Mutations that confer RIFR in E. coli (above) 
and MTB (below) are indicated (Zhou et al., 2013, Sandgren et al., 2009). Three major RIFR 
mutation sites are labeled. Mutations unique for E. coli RNAP are shown in blue, mutations 
unique for MTB RNAP are shown in red, and mutations found in both RNAPs are shown in 
black. 
(B) The structure of the RIF binding pocket. For clarity, only the β subunit (depicted as a ribbon 
model) is shown with the RMP stick model. The RRDRs and fork loop 2 are labeled. Three RIFR 
mutation sites investigated in this work are shown as black spheres at their Cα atoms and labeled. 
 
Figure 3. Preparations of RIF
R
 E. coli and MTB RNAPs 
(A) SDS-PAGE of purified WT and RIFR E. coli (left) and MTB RNAPs (right). 
(B) Determination of contaminating endogenous E. coli RNAP found in the E. coli RIFR RNAPs 
(left) and the MTB RIFR RNAPs (right) estimated by the in vitro transcription assay in the 
presence of 200 nM RMP. 
 
Figure 4. Structural basis of the RIF resistance by the S531L mutation 
(A) Fork loop 2 disordering upon RMP binding to S531L RNAP. The RIF binding sites of the 
WT RNAP•RMP (left) and the S531L RNAP•RMP (right) complexes are shown with the β 
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subunit (cyan, transparent molecular surfaces plus cartoon models) and the RMP (sphere 
models). In the left panel, fork loop 2 is colored blue and residue R540 is shown as a stick 
model. In the right panel, amino acid residues 532 and 541 that connect the disordered fork loop 
2 are indicated as blue circles. Area of the RMP naphthalene ring exposure to solvent due to 
disordering of fork loop 2 is indicated by a red arrow. 
(B) Proposed mechanism for RIF resistance by the S531L mutation in which RMP binding 
induces disordering of fork loop 2. 
 
Figure 5. Structural basis of the RIF resistance by the H526Y mutation 
(A) Comparison of the WT and H526Y mutant RNAPs. RNAP structures are depicted as ribbon 
models (WT, the same color as in Fig. 2B; H526Y, gray) and were superposed at their RRDRs. 
The H526Y side chain is shown as a stick model and labeled. Two regions of the β subunit that 
change their conformations between the WT and mutant RNAPs are shown as dashed ovals and 
labeled. 
(B) Steric hindrance of RMP binding to the H526Y mutant (left: the WT RNAP•RMP complex; 
right: the H526Y RNAP•RMP complex model). The β subunit and RMP are shown by molecular 
surface (cyan) and stick models (yellow), respectively. The four amino acid residues (Q513, 
F514, D516 and H526/H526Y) forming the binding surface of the ansa bridge (C16 to C25 side) 
of RMP are indicated. The WT RNAP•RMP complex and the H526Y structures were superposed 
with their RRDRs and RMP is overlaid on the H526Y structure to make the H526Y RNAP•RMP 
complex model (right). The locations of the clash between the ansa bridge of RMP with H526Y 
are indicated by arrows. 
 
Figure 6. Structural basis of RIF resistance by the D516V mutation 
(A) Electrostatic surfaces of the RIF binding pocket of the WT (left) and D516V mutant (right) 
RNAPs complexed with RMP (stick models). RNAP surfaces are colored with positive (blue), 
negative (red) and neutral (white) electrostatic potentials. Positions of the D516 residue in WT 
RNAP (left) and V516 residue in the mutant (right) are indicated by red circles. 
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SUMMARY: The bacterial RNA polymerase inhibitor Rifamycin and its derivative Rifampin 
has been used as a first line anti-tuberculosis treatment since 1960s and remains the cornerstone 
of current short-term TB treatment. The X-ray crystal structures of RNA polymerase containing 
clinically common Rifamycin resistant mutations RpoB-S531L, RpoB-H526Y and RpoB-D516V 
were determined and revealed that the molecular mechanisms of Rifamycin resistance by each 
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